Kereiakes DJ, Ellis SG, Metzger DC, et al. - Given that bioresorbable vascular scaffold (BVS) vs cobalt chromium everolimus-eluting stents was associated with noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization) at 1 year in the ABSORB III trial, and a rise in the adverse event rates (especially target vessel myocardial infarction and scaffold thrombosis) following BVS was evident between 1 and 3 years and cumulative to 3 years, researchers examined clinical results from ABSORB III to evaluate clinical consequences following BVS through 5 years, including beyond the 3-year time point of complete scaffold resorption. Findings revealed increased cumulative 5-year adverse event rates following BVS vs everolimus-eluting stents in the ABSORB III trial. However, they noted that the period of excess risk for BVS terminated at 3 years, coincident with complete scaffold resorption.